SCHEMBL784673

SCHEMBL784673

NC(=O)c1cn(F)c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.44
IDO1 P14902 1/20 0.44
FABP4 P15090 1/20 0.44
HTT P42858 1/20 0.42
ALDH1A1 P00352 4/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ATM Q13315 2/20 0.42
CNR1 P21554 1/20 0.42
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
OPRL1 P41146 1/20 0.41
NR4A2 P43354 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 2/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL785178 0.83 AKR1C3 (0.49) KDM4EFABP4HTTALDH1A1NR4A2
SCHEMBL10596904 0.81 KDM4E (0.50) KDM4EIDO1FABP4HTTALDH1A1
SCHEMBL4352139 0.79 KMT2A (0.47) KDM4EIDO1FABP4HTTALDH1A1
SCHEMBL2174829 0.78 NR4A2 (0.65) KDM4EHTTALDH1A1KMT2AMEN1
SCHEMBL21725009 0.78 KMT2A (0.49) KDM4EFABP4ALDH1A1KMT2AMEN1
SCHEMBL15558170 0.77 NR4A2 (0.69) KDM4EALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL5137040 0.77 NR4A2 (0.47) KDM4EHTTALDH1A1KMT2AMEN1
SCHEMBL27387445 0.76 KMT2A (0.48) KDM4EFABP4ALDH1A1KMT2AMEN1
SCHEMBL579403 0.76 MAP2K2 (0.40) KDM4EALDH1A1KMT2AMEN1CNR1
SCHEMBL579555 0.75 NR4A2 (0.65) KDM4EFABP4ALDH1A1NR4A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3347349-A1 FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Suven Life Sciences Limited (IN) 2018-07-18 EP disclosed
WO-2017042643-A1 FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2017-03-16 WO disclosed
US-8841302-B2 HCV inhibitor and therapeutic agent combinations PTC THERAPEUTICS, INC. (US) 2014-09-23 US disclosed
US-8735414-B2 Indole derivatives and methods for antiviral treatment PTC THERAPEUTICS, INC. (US) 2014-05-27 US disclosed
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT PTC THERAPEUTICS, INC. (US) 2012-07-19 US disclosed
US-20120070412-A1 HCV Inhibitor and Therapeutic Agent Combinations PTC THERAPEUTICS, INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070412-A1 HCV Inhibitor and Therapeutic Agent Combinations HAVCR2, SERPINB1, ENPEP KDM4E 4208/4885IDO1 1422/4885FABP4 2990/4885
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT IDO1, IRF3, MAVS KDM4E 886/4885IDO1 1/4885FABP4 3678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.